Full-Time
Assistant Accountant
Norgine
1,001-5,000 employees
European specialty pharma focused on gastroenterology
No salary listed
Hengoed, UK
In Person
 Accounting (1) |
|---|
Get referred to Norgine
See people who can refer or advise you
- AAT qualification or studying towards ACCA, CIMA, or ACA, or previous experience in an accounting, finance, or similar field.
- Strong understanding of month-end accounting processes, journals, accruals, and reconciliations.
- Strong understanding of fixed asset accounting, tax reporting, and audit support.
- Ability to manage multiple priorities and meet deadlines while communicating clearly and effectively with team members.
- Proficiency in Microsoft Office applications and experience using SAP, BlackLine, or similar systems.
- Knowledge of internal controls and compliance requirements.
- Complete month-end close activities accurately and on time, escalating issues where appropriate.
- Prepare and post journals, including accruals, prepayments, cash, and accounting adjustments.
- Perform balance sheet reconciliations and resolve outstanding discrepancies.
- Maintain fixed asset registers, ensuring accurate accounting for additions, disposals, and depreciation.
- Support tax and statutory reporting requirements, including VAT, corporate tax, and other local filings.
- Provide timely support during internal and external audits.
- Prepare regulatory and statistical submissions.
- Assist Accounting Managers with day-to-day accounting activities and financial reporting.
- Analyse financial data and prepare standard reports to support business decision-making.
- Contribute to process improvements and the enhancement of accounting controls and reconciliation processes.
- Ensure compliance with financial policies, controls, regulations, and best practice.
Norgine is a European specialty pharmaceutical company focused on gastroenterology. It develops, markets, and distributes prescription medicines, including MOVICOL, an osmotic laxative that draws water into the stool to relieve constipation. Its products target GI disorders and are sold mainly in Europe, leveraging a long family-ownership legacy until 2022 when Goldman Sachs Asset Management's private equity arm acquired a majority stake to speed growth through acquisitions and new products. The goal is to expand its platform by adding new therapies and strategic acquisitions to strengthen its position in the European market.
Company Size
1,001-5,000
Company Stage
Acquired
Total Funding
N/A
Headquarters
Amsterdam, Netherlands
Founded
1906
Get referred to Norgine
See people who can refer or advise you
Simplify's Take
What believers are saying
- March 2026 Hengoed expansion adds 44 jobs and over £50 million invested since 2022.
- March 2026 Swissmedic and TGA approvals broaden PEDMARQSI revenue across two major markets.
- April 2025 Theravia acquisition and January 2025 XOLREMDI license deepen rare-disease portfolio scale.
What critics are saying
- MOVICOL faces generic erosion, echoing Norgine's 2008 German device-versus-drug fight.
- Theravia integration and multiple rare-disease launches strain management after Janneke van der Kamp's 2025 handover.
- XOLREMDI depends on X4 supply and authorization transfers, concentrating partner execution risk.
What makes Norgine unique
- PEDMARQSI is first-in-class pediatric ototoxicity prevention across Europe and Australia, 2026.
- Norgine commercializes XOLREMDI for WHIM syndrome in Europe, Australia, and New Zealand.
- Hengoed manufactures 50 million packages yearly, anchoring supply and launch execution.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Training Programs
Company News
From Oxfordshire to Wales: where UK Life Sciences investment is going in 2026. Cambridge is one of several UK life sciences hubs attracting new investment in R&D, manufacturing and biopharma infrastructure. From clinical cleanrooms in Birmingham to mRNA manufacturing in Oxfordshire, new investment is adding research and production capacity across the UK life sciences sector. The UK life sciences sector generates approximately $200 billion (£147 billion) in annual turnover and employs around 360,000 people. Nearly half of these jobs are located outside London, the East and South East of England. In July 2026, the UK government reported that the country had attracted more than $4.1 billion (£3 billion) in public-private life sciences investment over the previous 12 months. Pharma investment reaches Cambridge, Oxfordshire and surrey. AstraZeneca is investing approximately $408 million (£300 million) across its Cambridge headquarters and Macclesfield operations, including work using AI in drug discovery. Moderna has also opened its Innovation and Technology Centre at Harwell in Oxfordshire as part of its 10-year, around $1.36 billion (£1 billion) UK R&D commitment. The site combines clinical R&D with mRNA drug substance manufacturing and has capacity to produce up to 100 million vaccine doses during endemic periods, rising to 250 million during a pandemic. Around $680 million (£500 million) is being invested in UCB's new R&D and biologics manufacturing facility in Windlesham. The project is expected to support up to 240 jobs. Xtalks Insights Protected by reCAPTCHA. What topics would you like to hear more about? Select all that apply. Want to get even more specific? Help us narrow down the sub-topics that you're most interested in. For webinars, videos, podcasts and more from Xtalks, join our community today. Manufacturing investment extends across the UK. In April 2026, the UK government announced more than $109 million (£80 million) in investment across several life sciences manufacturing projects. Accord Healthcare is investing more than $61 million (£45 million) in Barnstaple, North Devon, to increase local production of newer medicines, including treatments for bipolar disorder, while maintaining its generic medicine operations. In Birmingham, approximately $13.6 million (£10 million) is going toward a near-patient biomanufacturing facility at the Precision Health Technologies Accelerator. The site will include three cleanrooms for medicines, vaccines and clinical trial materials, including cell and gene therapies and mRNA vaccines. In Wales, specialty pharmaceutical company Norgine is investing more than $27 million (£20 million) at its Hengoed site to expand production of gastrointestinal medicines and upgrade manufacturing capacity. Public investment is also being used to bring in private capital. The government says around $156 million (£115 million) allocated through the Life Sciences Innovative Manufacturing Fund has helped secure more than $894 million (£657 million) in private investment across 10 projects. Those projects are expected to create 487 jobs and safeguard another 1,330. In August 2026, the UK government released eligibility rules for its Life Sciences Large Investment Portfolio to encourage major life sciences projects in the country. To qualify for support, companies must plan to invest at least $340 million (£250 million) in UK-based R&D or manufacturing over three years, with at least one eligible project beginning within 12 months. If you want your company to be featured on Xtalks.com, please email [email protected].
Norgine has received Australian Therapeutic Goods Administration registration for PEDMARQSI (sodium thiosulfate anhydrous) for preventing cisplatin-induced hearing loss in children aged one month to under 18 years with localised, non-metastatic solid tumours. PEDMARQSI is the first and only treatment registered in Australia for preventing cisplatin-induced ototoxicity in paediatric patients. Cisplatin chemotherapy carries substantial risk of permanent hearing loss, which can affect speech development, education and quality of life in children. The TGA registration is based on data from two Phase 3 clinical trials. The approval follows previous authorisations in Europe, the United Kingdom and Switzerland. PEDMARQSI is not currently included on Australia's Pharmaceutical Benefits Scheme. Norgine is a European specialty pharmaceutical company with 1,500 employees generating approximately $650 million in annual sales.
Norgine has received European Commission marketing authorisation for XOLREMDI (mavorixafor), the first approved treatment for WHIM syndrome in the European Union. The approval, granted under exceptional circumstances, follows a positive opinion from the EMA's Committee for Medicinal Products for Human Use. XOLREMDI is indicated for patients aged 12 and older with WHIM syndrome, an ultra-rare primary immunodeficiency that impairs white blood cell release from bone marrow, increasing infection risk. The approval is supported by results from a pivotal Phase 3 trial involving 31 patients. Norgine will commercialise mavorixafor across Europe, Australia and New Zealand under a licensing agreement with X4 Pharmaceuticals announced in January 2025. The company will handle market access and commercialisation, whilst X4 will manufacture and supply the treatment.
Norgine has announced that Swissmedic has approved PEDMARQSI (sodium thiosulfate solution for infusion) for preventing cisplatin-induced hearing loss in children aged 1 month to under 18 years with localised, non-metastatic solid tumours. It becomes the first and only treatment authorised in Switzerland for this indication. The approval is based on two open-label, randomised Phase 3 trials, SIOPEL 6 and COG ACCL0431, which showed approximately 50% reduction in cisplatin-induced ototoxicity compared with cisplatin alone, whilst maintaining chemotherapy efficacy. PEDMARQSI previously received paediatric use marketing authorisation from the European Medicines Agency in May 2023 and national marketing authorisation in the UK. Amsterdam-based Norgine is a mid-sized pharmaceutical company generating approximately $650 million in annual sales.
Pharmaceutical company Norgine is investing £23 million and creating 44 jobs at its manufacturing plant in Hengoed, Caerphilly. The expansion will increase warehousing and production space to meet growing demand for essential medicines across the UK. The investment has been enabled by the UK Government's Life Sciences Innovative Manufacturing Fund, part of the Life Sciences Sector Plan. Wales's life sciences sector generated over £3.5 billion in turnover and employed more than 13,000 people across 280 companies in 2023/24. Norgine has operated in Wales for 60 years and partners with Cardiff University and regional colleges for talent development. Secretary of State for Wales Jo Stevens announced the expansion whilst launching a new international programme to attract further investment to Wales, which secured nearly 5% of UK inward investment projects in 2024/25.